title: Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.
abstract: The increasing incidence of carbapenem-resistant Klebsiella pneumoniae (CR-KP) fundamentally alters the management of patients at risk to be colonized or infected by such microorganisms. Owing to the limitation in efficacy and potential for toxicity of the alternative agents, many experts recommend using combination therapy instead of monotherapy in CR-KP-infected patients. However, in the absence of well-designed comparative studies, the best combination for each infection type, the continued role for carbapenems in combination therapy and when combination therapy should be started remain open questions. Herein, the authors revise current microbiological and clinical evidences supporting combination therapy for CR-KP infections to address some of these issues.
authors: 2nd Division of Infectious Diseases, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy.
authors: Nicola
authors: N
authors: Petrosillo
authors: Maddalena
authors: M
authors: Giannella
authors: Russell
authors: R
authors: Lewis
authors: Pierluigi
authors: P
authors: Viale
mesh_terms: D000617:Aminoglycosides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D015780:Carbapenems / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003091:Colistin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005578:Fosfomycin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007710:Klebsiella Infections / Q000188:drug therapy* / Q000453:epidemiology; D007711:Klebsiella pneumoniae / Q000187:drug effects*; D008911:Minocycline / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D012307:Risk Factors; D000078304:Tigecycline
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D015780:Carbapenems; D005578:Fosfomycin; D000078304:Tigecycline; D008911:Minocycline; D012293:Rifampin; D003091:Colistin